September 7th 2023
INT230-6 is an investigational product candidate made up of cisplatin, vinblastine, and a penetration enhancer molecule being evaluated for patients with soft tissue sarcoma.
FDA Places Partial Clinical Hold on Study of FHD-609 in Synovial Sarcoma
April 25th 2023A patient treated with the second highest dose level of FHD-609 had a grade 4 adverse event. Enrollment in the study of the agent in patients with synovial sarcoma or SMARCB-1 deleted tumors has been halted.
Read More
Link Between pCR and Improved Survival for Patients With Soft Tissue Sarcoma
April 4th 2023Data from an analysis of the combined NRG-RTOG 0630/9514 trials show that pathologic complete response can be used as a prognostic factor for clinical outcomes in future research of patients with soft tissue sarcoma.
Read More
Taking on the Challenge to Develop New Therapies for Pediatric Solid Tumors
January 31st 2023Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.
Read More
Bringing Targeted Agents from Clinical Trials to the Clinic for Patients With Uterine Sarcoma
December 23rd 2022In an interview with Targeted Oncology, Matthew A. Ingham, MD, explains the uniqueness of uterine sarcomas and how years of research around these tumors have led to advances in precision medicine for patients.
Read More
Afami-cel Elicits Durable Responses With Tolerable Safety in Pre-Treated Synovial Sarcoma
November 22nd 2022With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.
Read More
Nivolumab and Ipilimumab Shows Promising Responses in Advanced Classical Kaposi Sarcoma
August 9th 2022Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.
Read More
Selinexor Showed Longer PFS Vs Placebo in Patients with Advanced, Metastatic DD-LPS
May 5th 2022Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.
Read More
Promising ICIS Are Explored in Sarcoma, But Disparate Histologies Are Challenging
March 22nd 2022Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.
Read More
Ripretinib Stills Holds a Place in the Advanced GIST Landscape After INTRIGUE Study
January 25th 2022Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.
Read More